Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation.
In a randomized, double blinded study, 23-valent pneumococcal polysaccharide vaccine (PSV) or conjugate Haemophilus influenzae type b (HbOC) vaccine was administered to 60 healthy women in the third trimester of gestation. Total IgG, IgG1, and IgG2 antibodies to pneumococcal serotypes 6B, 14, 19F and 23F were measured by ELISA in mothers prior to immunization, at delivery and 7 months after delivery, and in infants at birth (cord blood), 2 and 7 months after delivery. IgA was evaluated in breast milk at 2 and 7 months, and opsonophagocytic activity in cord blood. PSV was safe and immunogenic in pregnant women. Transplacental transmission of vaccine-specific antibodies was efficient. Maternal immunization with PSV resulted in significantly higher concentrations of pneumococcal antibodies in infants at birth and at 2 months of age, and greater functional opsonophagocytic activity of passively acquired IgG antibody.
Munoz
F M
FM
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA. florm@bcm.tmc.edu
Englund
J A
JA
Cheesman
C C
CC
Maccato
M L
ML
Pinell
P M
PM
Nahm
M H
MH
Mason
E O
EO
Kozinetz
C A
CA
Thompson
R A
RA
Glezen
W P
WP
D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D002353:Carrier State / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D007231:Infant, Newborn; D008895:Milk, Human / Q000276:immunology; D009297:Nasal Mucosa / Q000382:microbiology; D009895:Opsonin Proteins / Q000097:blood; D010587:Phagocytosis; D011008:Pneumococcal Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy; D011263:Pregnancy Trimester, Third; D011446:Prospective Studies; D012449:Safety; D013296:Streptococcus pneumoniae / Q000276:immunology / Q000302:isolation & purification
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D009895:Opsonin Proteins; D022242:Pneumococcal Vaccines